← Issue №16/ week of Oct 18, 2026/Colorectal

Oncologic Outcomes and Adjuvant Chemotherapy Use in Early- Versus Late-Onset Colon Cancer: A Propensity Score-Matched Analysis.

From GI Signals issue №16: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal retrospective · n=2,624 · Oct 16, 2026 · Dis Colon Rectum · IF 3.5

Oncologic Outcomes and Adjuvant Chemotherapy Use in Early- Versus Late-Onset Colon Cancer: A Propensity Score-Matched Analysis.

New evidencecolorectal cancerepidemiology
Clinical takeawayAge under 50 by itself is not a reason to give adjuvant chemotherapy in stage II colon cancer; base the decision on T4, nodal status, grade and the other high-risk features as in older patients. The study cannot say whether the extra chemotherapy helped.
What it foundFive-year recurrence-free survival did not differ between early-onset (88.0%) and late-onset (86.1%) colon cancer patients (p = 0.09). Early-onset patients received adjuvant chemotherapy more frequently, including in low-risk Stage II disease.
ContextSingle-centre retrospective matched cohort (656 early-onset vs 1968 late-onset); few early-onset patients went untreated, so age-specific chemotherapy benefit is not estimable.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Oh SY … Lim SB · Diseases of the Colon and Rectum · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №16 Every paper GI Signals surfaces gets a page like this one. All issues